- Pamidronic acid
IUPAC_name = (3-amino-1-hydroxy-1-phosphono-propyl)phosphonic acid
CAS_number = 40391-99-9
ATC_prefix = M05
ATC_suffix = BA03
PubChem = 4674
DrugBank = APRD01161
C = 3 | H = 11 | N = 1 | O = 7 | P = 2
molecular_weight = 235.07 g/mol
bioavailability = n/a
protein_bound = 54%
metabolism = Nil
elimination_half-life = 28 ± 7 hours
excretion = Renal
pregnancy_AU = B3
pregnancy_US = D
legal_UK = POM
legal_US = Rx-only
routes_of_administration = Intravenous
Pamidronic acid (INN) or pamidronate disodium (USAN), pamidronate disodium pentahydrate is a nitrogen containing
bisphosphonate, used to prevent osteoporosis. It is marketed by Novartisunder the brand name Aredia.
It is used to prevent
boneloss, and treat osteoporosis. It is also used to strengthen bone in Paget's disease, to prevent bone loss due to steroid use, and in certain cancers with high propensity to bone, such as multiple myeloma. In multiple myeloma, it is usually administered as an intravenous infusion, lasting about 3 hours. The therapy is repeated monthly, and lasts for the life of the patient. Due to its ability to sequester calciumin bone, it is also used to treat high calcium levels.It is also used as an experimental treatment of the bone disorder known as Osteogenesis Imperfecta, or brittle bones.
Intravenous, usually 90 mg monthly. 30 mg, 60 mg, and 90 mg vials are available, mixed with mannitol.
Common side effects include bone pain, low calcium levels,
nausea, and dizziness. Osteonecrosis of the jawis a rare complication which has been associated with the use of bisphosphonates, including pamidronate.cite journal | author = Zarychanski R, Elphee E, Walton P, Johnston J | title = Osteonecrosis of the jaw associated with pamidronate therapy. | journal = Am J Hematol | volume = 81 | issue = 1 | pages = 73–5 | year = 2006 | pmid = 16369966 | doi = 10.1002/ajh.20481]
Pamidronate activates human γδ T cells "
in vitro" and " in vivo", which may lead to flu-like symptoms upon administration.
Wikimedia Foundation. 2010.